Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The last earnings update was 59 days ago. More info.
Benitec Biopharma has significant price volatility in the past 3 months.
BJ9 underperformed the Biotechs industry which returned -5.6% over the past year.
BJ9 underperformed the Market in Germany which returned -4.5% over the past year.
Is Benitec Biopharma undervalued based on future cash flows and its price relative to the stock market?
Here we compare the current share price of Benitec Biopharma to its discounted cash flow analysis.value.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Benitec Biopharma.
The calculations below outline how an intrinsic value for Benitec Biopharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
Amount off the current price Benitec Biopharma is available for.
For Benitec Biopharma to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
Benitec Biopharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
Benitec Biopharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
The amount the stock market is willing to pay for Benitec Biopharma's earnings, growth and assets is considered below, and whether this is a fair price.
Are Benitec Biopharma's earnings available for a low price, and how does this compare to other companies in the same industry?
** Primary Listing of Benitec Biopharma.
Benitec Biopharma is good value based on earnings compared to the Europe Biotechs industry average.
Benitec Biopharma is good value based on earnings compared to the Germany market.
Does Benitec Biopharma's expected growth come at a high price?
Unable to calculate PEG ratio for Benitec Biopharma, we can't assess if its growth is good value.
What value do investors place on Benitec Biopharma's assets?
* Primary Listing of Benitec Biopharma.
Benitec Biopharma is good value based on assets compared to the DE Biotechs industry average.
Benitec Biopharma has a total score of 5/6, see the detailed checks below.
How is Benitec Biopharma expected to perform in the next 1 to 3 years based on estimates from 0 analysts?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company's ability to generate profit. But as Benitec Biopharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
Is Benitec Biopharma expected to grow at an attractive rate?
Unable to compare Benitec Biopharma's earnings growth to the low risk savings rate as no estimate data is available.
Unable to compare Benitec Biopharma's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Benitec Biopharma's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Benitec Biopharma is high growth as no earnings estimate data is available.
Unable to determine if Benitec Biopharma is high growth as no revenue estimate data is available.
All data from Benitec Biopharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
Unable to establish if Benitec Biopharma will efficiently use shareholders' funds in the future without estimates of Return on Equity.
Examine whether Benitec Biopharma is trading at Benitec Biopharma'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
Benitec Biopharma's competitive advantages and company strategy can generally be found in its financial reports archived here.
Benitec Biopharma has a total score of 0/6, see the detailed checks below.
How has Benitec Biopharma performed over the past 5 years?
Below we compare Benitec Biopharma's growth in the last year to its industry (Biotechs).
Benitec Biopharma's year on year earnings growth rate has been positive over the past 5 years.
Benitec Biopharma has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
Benitec Biopharma has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Benitec Biopharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Benitec Biopharma has not efficiently used shareholders' funds last year (Return on Equity less than 20%).
Benitec Biopharma used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
Benitec Biopharma has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
Benitec Biopharma has a total score of 2/6, see the detailed checks below.
How is Benitec Biopharma's financial health and their level of debt?
The boxes below represent the relative size of what makes up Benitec Biopharma's finances.
Benitec Biopharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Benitec Biopharma's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of Benitec Biopharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Benitec Biopharma has no debt, it does not need to be covered by short term assets.
All data from Benitec Biopharma Company Filings, last reported 3 months ago.
Benitec Biopharma has no debt.
Benitec Biopharma has not taken on any debt in the past 5 years.
Benitec Biopharma has no debt, it does not need to be covered by operating cash flow.
Benitec Biopharma has no debt, therefore coverage of interest payments is not a concern.
Benitec Biopharma has a total score of 6/6, see the detailed checks below.
What is Benitec Biopharma's current dividend yield, its reliability and sustainability?
Current annual income from Benitec Biopharma dividends.
If you bought €2,000 of Benitec Biopharma shares you are expected to receive €0 in your first year as a dividend.
Unable to evaluate Benitec Biopharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Benitec Biopharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Benitec Biopharma has not reported any payouts.
Unable to verify if Benitec Biopharma's dividend has been increasing as the company has not reported any payouts.
What portion of Benitec Biopharma's earnings are paid to the shareholders as a dividend.
Unable to calculate sustainability of dividends as Benitec Biopharma has not reported any payouts.
What is the CEO of Benitec Biopharma's salary, the management and board of directors tenure and is there insider trading?
Dr. Jerel A. Banks, Ph.D., M.D. has been Chief Executive Officer of Benitec Biopharma Limited since June 26, 2018. Dr. Banks serves as Chief Investment Officer of NantVentures. Dr. Banks has been Senior Vice President of Mergers and Acquisitions at NantKwest, Inc. since September 22, 2015. Dr. Banks serves as a Vice President, Portfolio Manager and Research Analyst at Franklin Advisers, Inc. Dr. Banks serves as Vice President, Portfolio Manager and Research Analyst at Franklin Templeton Investments. Dr. Banks served as Portfolio Manager and Research Analyst at Franklin Templeton Investment Funds SICAV - Franklin Biotechnology Discovery Fund and Franklin Strategic Series - Franklin Biotechnology Discovery Fund. Dr. Banks joined Franklin Templeton Investments in 2012. Previously, Dr. Banks served as a Senior Equity Research Analyst covering the biotechnology sector and Financial Analyst at Sectoral Asset Management Inc., and Apothecary Capital. Dr. Banks served as an Equity Research Associate on the healthcare investment team at Capital Research and Management. Dr. Banks serves as the Executive Chairman of the Board at Benitec Biopharma Limited since June 15, 2018 and served as its Chairman of the Board from October 12, 2017 to June 15, 2018. Dr. Banks served as a Non-Executive Director of Benitec Biopharma Limited from October 26, 2016 to June 15, 2018. Dr. Banks received an M.D. and Ph.D. in Organic Chemistry from Brown University and holds a B.A. in Chemistry from Princeton University.
Jerel's compensation has increased in line with Benitec Biopharma recently becoming profitable.
Jerel's remuneration is lower than average for companies of similar size in Germany.
The tenure for the Benitec Biopharma management team is about average.
The tenure for the Benitec Biopharma board of directors is about average.
Benitec Biopharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. It also offers BB-401 and BB-501 for the treatment of oncology related to head and neck squamous cell carcinoma. The company was founded in 1995 and is headquartered in North Sydney, Australia.